2026-06-05T12:45:30Zhttps://riuma.uma.es/rest/oai/request

oai:riuma.uma.es:10630/247812026-02-03T11:52:27Zcom_10630_2254col_10630_37959

Neuroprotective effects of insulin-like growth factor II in a mouse model of Parkinson's disease Ladrón de Guevara-Miranda, David Martín-Montañez, Elisa Valverde, Nadia Lara, Estrella Romero-Zerbo, Silvana Yanina Millón-Peñuela, Carmelo Boraldi, Federica Ávila-Gámiz, Fabiola Pérez-Cano, Ana María Garrido-Gil, Pablo Labandeira-García, José Luis Santín-Núñez, Luis Javier Pavía-Molina, José García-Fernández, María Inmaculada Parkinson, Enfermedad de - Congresos Medicamentos - Ensayos - Congresos Medicamentos - Efectividad - Congresos Experimentación animal - Congresos Progressive degeneration of the nigrostriatal dopaminergic pathway is a core, currently irreversible pathological hallmark of Parkinson’s disease (PD) that leads to a variety of motor and non-motor symptoms. Here, we aimed to study the potential neuroprotective effects of insulin-like growth factor II (IGF-II) in a PD mouse model based on the chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and probenecid (MPTP/p), which induces loss of dopaminergic neurons in the Substantia Nigra pars compacta (SNc). Male C57BL6/J mice (N=36) received a 5-week treatment with MPTP/p (or vehicle) and were co-treated with chronic IGF-II (or saline) from either the beginning of the procedure (plus an additional week, days 1-44) or once the MPTP/p insult was already triggered (days 21-44). Baseline and post-treatment measurements for motor performance in the Rotarod and self-grooming in an Open Field were taken. Likewise, dopaminergic (TH, DAT) and neuroinflammatory-related (GFAP) markers in the SNc and the dorsal striatum were studied by immunohistochemistry. Our results revealed that both early and delayed IGF-II co-treatment were successful in preventing motor and behavioral impairment in the MPTP/p model. Moreover, chronic IGF-II protected against MPTP/p-induced loss of dopaminergic neurons in the SNc and promoted a significant recovery of dopaminergic activity in the terminals located in the dorsal striatum, further reducing reactive astrocytosis in these brain regions. Thus, we demonstrated the neuroprotective role of IGF-II in a mouse model of PD, highlighting its potential as a promising therapeutical target for treating this disease. Funding: UMA18-FEDERJA-004, PID2020-113806RB-I00. Universidad de Málaga, Campus de Excelencia Internacional Andalucía Tech. 2022-07-26T09:42:01Z 2022-07-26T09:42:01Z 2022-07-20 conference output https://hdl.handle.net/10630/24781 eng IV International Congress of Psychobiology Valencia, España 20/07/2022 open access